Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2

  • Hippisley-Cox J
  • Coupland C
  • Vinogradova Y
 et al. 
  • 1


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Cardiovascular disease (CVD) due to atherosclerosis of the arterial vessel wall and to thrombosis is the foremost cause of premature mortality and of disability-adjusted life years (DALYs) in Europe, and is also increasingly common in developing countries.1 In the European Union, the economic cost of CVD represents annually E192 billion1 in direct and indirect healthcare costs. The main clinical entities are coronary artery disease (CAD), ischaemic stroke, and peripheral arterial disease (PAD). The causes of these CVDs are multifactorial. Some of these factors relate to lifestyles, such as tobacco smoking, lack of physical activity, and dietary habits, and are thus modifiable. Other risk factors are also modifiable, such as elevated blood pressure, type 2 diabetes, and dyslipidaemias, or non-modifiable, such as age and male gender. These guidelines deal with the management of dyslipidaemias as an essential and integral part of CVD prevention. Prevention and treatment of dyslipidaemias should always be considered within the broader framework of CVD prevention, which is addressed in guidelines of the Joint European Societies’ Task forces on CVD prevention in clinical practice.2 – 5 The latest version of these guidelines was published in 20075; an update will become available in 2012. These Joint ESC/European Atherosclerosis Society (EAS) guidelines on the management of dyslipidaemias are complementary to the guidelines on CVD prevention in clinical practice and address not only physicians [e.g. general practitioners (GPs) and cardiologists] interested in CVD prevention, but also specialists from lipid clinics or metabolic units who are dealing with dyslipidaemias that are more difficult to classify and treat.

Author-supplied keywords

  • Adherence
  • Anticholesteremic Agents/therapeutic use
  • Atherosclerosis
  • Cardiovascular Diseases/etiology
  • Cardiovascular risk
  • Children
  • Cholesterol
  • Clinical recommendations
  • Diet
  • Dyslipidemia
  • Dyslipidemias/drug therapy/*prevention & control/*
  • Elderly
  • Human immunodeficiency virus
  • Humans
  • LDL/blood
  • Lifestyle therapies
  • Lipoproteins
  • Medical
  • Metabolic Syndrome X/complications/diagnosis
  • Residual risk
  • Rheumatoid arthritis
  • Risk Factors
  • Societies
  • Statins
  • Team-based care
  • adherence
  • apolipoprotein B
  • cholesterol
  • drugs
  • dyslipidaemias
  • high-density lipoproteins
  • lifestyle
  • lipoprotein remnants
  • low-density lipoproteins
  • total cardiovascular risk
  • treatment
  • triglycerides

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • J. Hippisley-Cox

  • C. Coupland

  • Y. Vinogradova

  • J. Robson

  • R. Minhas

  • A. Sheikh

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free